Navigation Links
Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
Date:8/29/2012

HORSHAM, Pa., Aug. 30, 2012 /PRNewswire/ -- Janssen Biotech, Inc. ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed a global license and development agreement with the Danish company Genmab A/S for the anti-cancer compound, daratumumab.  Daratumumab (HuMax®-CD38) is a human CD38 monoclonal antibody currently in Phase I/II studies in relapsed, refractory multiple myeloma. 

"Janssen was one of the first companies to recognize the power and promise of monoclonal antibodies and today is a world leader in biologics.  We look forward to applying that same expertise to daratumumab to help meet the needs of patients with multiple myeloma," said William N. Hait, M.D., Ph.D., head of Janssen Research & Development, LLC.  "Daratumumab is an exciting, innovative compound, and we are delighted to add it to our portfolio."

Under terms of the agreement, Genmab will grant Janssen an exclusive worldwide license to develop and commercialize daratumumab as well as a back-up CD38 human antibody.  Janssen has made an upfront payment and will make additional payments based upon the achievement of certain development, regulatory and sales milestones.  Genmab will be responsible for completing the GEN501 and GEN503 Phase I/II trials.  Janssen will be responsible for all other development, clinical and regulatory filing activities.  In addition, as part of the agreement, Johnson & Johnson Development Corporation, an affiliate of Janssen, will make an equity investment in Genmab.

The transaction is subject to customary closing conditions, including approval by the Danish Financial Supervisory Authority and clearance by the U.S. antitrust authorities.

About Daratumumab
Daratumumab is a human monoclonal antibody (mAb) with broad spectrum cytotoxic activity.  It targets the CD38 molecule, which is highly expressed on the surfac
'/>"/>

SOURCE Janssen Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
4. Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference
5. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
6. New Stroke Drug from ZZ Biotech Produced by Laureate Biopharma
7. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
8. German-based Contract Research Organization Verum.de Opens US Office to Expand Clinical Study Services in Central and Eastern Europe for American Pharma and Biotech
9. Antibiotics and Biotechnology Take Center Stage at Food Dialogues Event
10. Save Up To 25% on International Biotech and Healthcare, and Pharmaceutical Conferences by Registering Through GII
11. Kibow Biotech Marks Its Continued Growth with Relocation to Larger Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  AMRI (NASDAQ: ... announced a strategic collaboration focused on the development, ... active pharmaceutical ingredients, ("APIs"). The collaboration combines Saneca,s ... their expertise in developing and manufacturing controlled substance ... to tech transfer processes into these facilities. The ...
(Date:8/31/2015)... August 31, 2015 Premune ... into an exclusive licensing agreement for Redonyl ® ... $300 million USD veterinary dermatology market, is a nutritional ... support healthy skin in dogs and cats. Redonyl ® ... , and has been received positively in the ...
(Date:8/31/2015)... Aug. 31, 2015  QT Vascular Ltd., together with its ... with its subsidiaries, the "Group"), a global company ... advanced therapeutic solutions for the minimally invasive treatment ... of the below-the-knee ("BTK") cohort of patients in ... presented on August 15, 2015 at the 5th ...
Breaking Medicine Technology:AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4
... , April 29, 2010 Albireo today,announced ... recent study,assessing the safety, tolerability and efficacy of A3309 ... compound for,the treatment of irritable bowel syndrome with constipation ... during the 2010,Digestive Disease Week (DDW) annual meeting being ...
... SALT LAKE CITY , April 28 Sonic Innovations, ... Administration (VA), is conducting ongoing training events for government clinicians.  The company ... in San Diego, California and April 25 through ... for May 3 through 5 in Salt Lake City, ...
Cached Medicine Technology:Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 2Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 3Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 4Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 5Sonic Innovations Conducts National Training Events for Government Clinicians 2Sonic Innovations Conducts National Training Events for Government Clinicians 3
(Date:8/31/2015)... ... August 31, 2015 , ... Jvion, the Atlanta-based ... predictive use case focused on helping hospital perform under the Center for Medicare ... payments are adjusted based on performance across four domains related to care quality. ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dental clinicians ... University of Health Sciences to learn more about its integrated approach to diabetes ... Sciences and Institute of Cellular Medicine at Newcastle University, and Susan Bissett, National ...
(Date:8/31/2015)... ... August 31, 2015 , ... India Network Foundation, a non-profit ... tool, which summarizes all available plans, plan maximums, pre-existing condition coverage limits and ... help India Network members make an informed decision regarding the care they want ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... is a one-day event geared to patients and family members, medical professionals, ... local and regional mesothelioma experts. The conference is a collaborative effort between the ...
(Date:8/31/2015)... Vista, CA (PRWEB) , ... August 31, 2015 , ... ... house on Saturday, September 5, 2015, from 11 a.m. to 3 p.m. near Albertsons ... prizes, and the opportunity to meet Dr. Ofelia Rivera and Dr. Jay Lopp. Call ...
Breaking Medicine News(10 mins):Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3
... Care Recommendations, WASHINGTON, Dec. 3 The ... for Quality Long-Term Care,for its efforts to raise ... year,s Presidential candidates. We urge Presidential,candidates and members ... our nation faces and to work to propose ...
... HSKA ) today announced it will present ... 6, 2007 at the Grand Hyatt Denver, 1750 ... to begin at 5:05,p.m. Mountain Time., (Logo: ... Corporation (NASDAQ: HSKA ) sells advanced veterinary ...
... 35 Conditions, YONKERS, N.Y., Dec. 3 ... patients, especially,when it comes to prescription drugs. That,s ... Consumer Reports, in which CR summarizes key findings ... 35 conditions including,Alzheimer,s disease, heart disease, high blood ...
... U.S. government studies show strong link to recreational drugs ... Two new U.S. studies of gay and bisexual men ... more than one-third have recently had unprotected intercourse. , ... sex with other HIV-infected men -- a practice called ...
... 3 Targeted Genetics Corporation,(Nasdaq: TGEN ) ... (NIH),Recombinant DNA Advisory Committee,s (RAC) assessment of the ... Phase I/II trial of,tgAAC94 for inflammatory arthritis., ... was a result of,complications from an opportunistic infection, ...
... a national,campaign encouraging Americans to Be Red Cross Ready, ... CPR for Everyone kit -- an at-home,tool for practicing ... CPR for Everyone kit is a portable, reasonably priced,practice ... office, in classrooms or,anywhere it is convenient to practice ...
Cached Medicine News:Health News:NCOA Commends Long Term Care Commission Report 2Health News:Consumer Reports 'Best Buy Drugs' Compares Best Medicines for Less 2Health News:Consumer Reports 'Best Buy Drugs' Compares Best Medicines for Less 3Health News:One-Third of HIV-Infected Gay Men Have Unsafe Sex: CDC 2Health News:One-Third of HIV-Infected Gay Men Have Unsafe Sex: CDC 3Health News:One-Third of HIV-Infected Gay Men Have Unsafe Sex: CDC 4Health News:Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis 2Health News:Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis 3Health News:Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis 4Health News:American Red Cross Offers Compression-Only CPR Practice Kit 2
Hemagglutination slide test for the qualitative and quantitative detection of Rheumatoid Factor in serum or synovial fluid....
Hemagglutination slide test for the differential qualitative detection and quantitative determination of infectious mononucleosis and other heterophile antibodies in serum or plasma....
Color-enhanced hemagglutination slide test for the rapid qualitative and semi-quantitative detection of infectious mononucleosis heterophile antibodies in serum or plasma....
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
Medicine Products: